Dietary interventions for multiple sclerosis

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Farinotti, Mariangela ^a   Simi, S ^b   Di Pietrantonj, C ^b   McDowell, N ^b   Brait, L ^b   Lupo, D ^b   Filippini, G ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b NONE

Author keywords

*Dietary supplements; Fatty acids, omega 3 administration dosage ; Fatty acids, unsaturated *administration dosage ; Humans; Multiple sclerosis *diet therapy ; Randomized controlled trials as topic

Indexed keywords

CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; DATA ANALYSIS; DATA EXTRACTION; DIET THERAPY; EMBASE; HUMAN; MEDLINE; METHODOLOGY; OUTCOME ASSESSMENT; REVIEW; RHEUMATOID ARTHRITIS; SAFETY; TREATMENT OUTCOME;

EID: 43049147352     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004192.pub2     Document Type: Review

References (115)

1. Bates 1977 {published data only} *Bates D, Fawcett PR, Shaw DA, Weightman D. Trail of polyunsaturated fatty acids in non-relapsing multiple sclerosis. British medical journal 1977;2(6092):932-3.
2. Shaw D. Trial of polyunsaturated fatty acids in multiple sclerosis [abstract]. Irish journal of medical science 1978;147(3):118.
3. Bates 1978 {published data only} *Bates D, Fawcett PR, Shaw DA, Weightman D. Polyunsaturated fatty acids in treatment of acute remitting multiple sclerosis. British Medical Journal 1978;2(6149):1390-1.
4. Shaw D. Trial of polyunsaturated fatty acids in multiple sclerosis [abstract]. Irish journal of medical science 1978;147(3):118.
5. Bates 1989 {published data only} *Bates D, Cartlidge NE, French JM, Jackson MJ, Nightingale S, Shaw DA, et al.A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry 1989;52(1):18-22.
6. Bates D, Cartlidge NEF, French JM. Results of a trial of N-3 polyunsaturated fatty acids in the treatment of multiple sclerosis [abstract]. Irish journal of medical science 1988;157(8):277.
7. Millar 1973 {published data only} *Millar JH, Zilkha KJ, Langman MJ, Wright HP, Smith AD, Belin J, et al.Double-blind trial of linoleate supplementation of the diet in multiple sclerosis. British medical journal 1973;1(5856):765-8.
8. Millar 1973 a {published data only} Millar JH, Zilkha KJ, Langman MJ, Wright HP, Smith AD, Belin J, et al.Double-blind trial of linoleate supplementation of the diet in multiple sclerosis. British medical journal 1973;1(5856):765-8.
9. Millar 1973 b {published data only} *Millar JH, Zilkha KJ, Langman MJ, Wright HP, Smith AD, Belin J, et al.Double-blind trial of linoleate supplementation of the diet in multiple sclerosis. British medical journal 1973;1(5856):765-8.
10. Paty 1978 {published data only} Paty DW. Double-blind trial of linoleic acid in multiple sclerosis. Archives of neurology 1983;40(11):693-4.
11. *Paty DW, Cousin HK, Read S, Adlakha K. Linoleic acid in multiple sclerosis: failure to show any therapeutic benefit. Acta neurologica Scandinavica 1978;58(1):53-8.
12. Weinstock-Guttman 05 {published and unpublished data} Weinstock-Guttman B, Baier M, Lee-Kwen P, Feichter J, Dinehart S, Venkatraman J, et al.A randomized study of low-fat diet with omega-3 fatty acid supplementation in patients with relapsing-remitting multiple sclerosis (RRMS). Neurology 2002;58:A461-2.
13. *Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher E, et al.Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins, leukotrienes, and essential fatty acids 2005;73(5):397-404.
14. Achiron 2003 Achiron A, Barak Y, Miron S, Izhak Y, Faibel M, Edelstein S. Alfa-calcidol treatment in multiple sclerosis. Clinical neuropharmacology 2003;26(2):53.
15. Cendrowski 1986 Cendrowski W. Multiple sclerosis and MaxEPA. The British journal of clinical practice 1986;40(9):365-7.
16. Dworkin 1984 Dworkin RH, Bates D, Millar JH, Paty DW. Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials. Neurology 1984;34(11):1441-5.
17. Ehrentheil 1952 Ehrentheil OF, Schulman MH, Alexander L. Role of food allergy in multiple sclerosis. Neurology 1952;2(5):412-26.
18. Fitzgerald 1987 Fitzgerald G, Harbige LS, Forti A, Crawford MA. The effect of nutritional counselling on diet and plasma EFA status in multiple sclerosis patients over 3 years. Human nutrition. Applied nutrition 1987;41(5):297-310.
19. Fleming 2000 Fleming JO, Hummel AL, Beinlich BR, Borowski BJ, Peebles T, Colburn M, et al.Vitamin D treatment of Relapsing-Remitting Multiple Sclerosis (RRMS): a MRI-based pilot study. Neurology 2000;54(Suppl 3):A338.
20. Gallai 1995 Gallai V, Sarchielli P, Trequattrini A, Franceschini M, Floridi A, Firenze C, et al.Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. Journal of neuroimmunology 1995;56(2):143-53.
21. Goldberg 1986 Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Medical hypotheses 1986;21(2):193-200.
22. Hewson 1984 Hewson DC. Is there a role for gluten-free diets inmultiple sclerosis?. Human nutrition. Applied nutrition 1984;38(6):417-20.
23. Horrobin 1979 Horrobin DF, Botez T, Botez MI. Polyunsaturated fatty acids and colchicine inmultiple sclerosis. Britishmedical journal 1979;1(6157):199-200.
24. Jensen 1986 Jensen GE, Clausen J. Glutathione peroxidase activity, associated enzymes and substrates in blood cells from patients with multiple sclerosis - effects of antioxidant supplementation. Acta pharmacologica et toxicologica 1986;59 Suppl 7:450-3.
25. Kira 1994 Kira J, Tobimatsu S, Goto I. Vitamin B12 metabolism and massive-dose methyl vitamin B12 therapy in Japanese patients with multiple sclerosis. Internal medicine (Tokyo, Japan) 1994;33(2):82-6.
26. Lakatos 2000 Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J, et al.Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Zeitschrift fur Rheumatologie 2000;59 Suppl 1:48-52.
27. Liversedge 1977 Liversedge LA. Multiple sclerosis research. Proceedings of a joint conference held by the Medical Research Council and the Multiple Sclerosis Society of Great Britain and Northern Ireland 17-18 October 1974. London: HMSO, 1975:236-237.
28. * Liversedge LA. Treatment and management of multiple sclerosis. British medical bulletin 1977;33(1):78-83.
29. Mahon 2003 Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. Journal of neuroimmunology 2003;134(1-2):128-32.
30. Mai 1990 Mai J, Sorensen PS, Hansen JC. High dose antioxidant supplementation to MS patients. Effects on glutathione peroxidase, clinical safety, and absorption of selenium. Biological trace element research 1990;24(2):109-17.
31. Meyer-Rienecker 1976 Meyer-Rienecker JH, Jenssen HL, Kohler H, Field EJ, Shenton BK. Effect of gamma-linolenate in multiple sclerosis. Lancet 1976;2(7992):966.
32. Munger 2004 Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willett WC, et al.Vitamin D intake and incidence of multiple sclerosis. Neurology 2004;62(1):60-5.
33. Nordvik 2000 Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta neurologica Scandinavica 2000;102(3):143-9.
34. Odinak 2002 Odinak MM, Bisaga GN, Zarubina IV. [New approaches to antioxidant therapy in multiple sclerosis] Russian. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2002;Suppl:72-5.
35. Paty 1975 Paty DW, Cousin HK, McDonald LE. Linoleic acid in multiple sclerosis. Lancet 1975;1(7917):1197-8.
36. Rosnowska 1980 Rosnowska M, Cendrowski W, Piesio B, Wieczorkiewicz M. [Effect of short-term administration of sunflower oil on the blood serum levelof linoleic and arachidonic acids and lipids inmultiple sclerosis]. Neurologia i neurochirurgia polska 1980;14(1):27-37.
37. Schultz 1984 Schultz A. Efficacy of cranberry juice and ascorbic acid in acidifying the urine in multiple sclerosis subjects. Journal of community health nursing 1984;1(3):159-69.
38. Schwarz 1970 Schwarz D. Microcirculatory therapy of multiple sclerosis. Italian [Terapia microcircolatoria della sclerosi a placche]. Minerva medica 1970;61(97):5543-61.
39. Shenton 1975 Shenton BK, Jenssen HL, Kohler H. Linoleic acid and multiple sclerosis: effect of prolonged administration on lymphocyte reactivity to antigen. IRCS Med Sci Cell Membr Biol 1975;3(10):503.
40. Swank 1990 Swank RL. Multiple sclerosis: fat-oil relationship. Nutrition (Burbank, Los Angeles County, Calif.) 1991;7(5):368-76.
41. Swank RL. Multiple sclerosis: twenty years on low fat diet. Archives of neurology 1970;23(5):460-74.
42. Swank RL. Treatment ofmultiple sclerosis with a low-fat diet. Journal of the American Dietetic Association 1960;36:322-5.
43. Swank RL. Treatment of multiple sclerosis with low-fat diet. A. M. A. archives of neurology and psychiatry 1953;69(1):91-103.
44. Swank RL. Treatment of multiple sclerosis with low-fat diet; results of five and one-half years' experience. A. M. A. archives of neurology and psychiatry 1955;73(6):631-44.
45. Swank RL. Treatment of multiple sclerosis with low-fat diet: result of seven years' experience. Annals of internal medicine 1956;45(5): 812-24.
46. Swank RL, Bourdillon RB. Multiple sclerosis: assessment of treatment with a modified low-fat diet. The Journal of nervous and mental disease 1960;131:468-88.
47. *Swank RL, Dugan BB. Effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet 1990;336(8706):37-9.
48. Swank RL, Goodwin J. Review of MS patient survival on a Swank low saturated fat diet. Nutrition (Burbank, Los Angeles County, Calif.) 2003;19(2):161-2.
49. Swank RL, Grimsgaard A. Multiple sclerosis: the lipid relationship. The American journal of clinical nutrition 1988;48(6):1387-93.
50. Wilmot VA, Swank RL. The influence of low-fat diet on blood lipid levels in health and in multiple sclerosis. The American journal of the medical sciences 1952;223(1):25-34.
51. Wade 2002 Loder C, Allawi J, Horrobin DF. Treatment of multiple sclerosis with lofepramine, L-phenylalanine and vitamin B12: mechanism of action and clinical importance: roles of the locus coeruleus and central noradrenergic systems. Medical hypotheses 2002;59(5):594-602.
52. Puri BK, Bydder GM, Chaudhuri KR, Al Saffar BY, Curati WL, White SJ, et al.MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine. Neuroreport 2001;12(9):1821-4.
53. *Wade DT, Young CA, Chaudhuri KR, Davidson DL. A randomised placebo controlled exploratory study of vitamin B12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry 2002;73(3):246- 9.
54. Wingerchuk 2005 Wingerchuk DM, Lesaux J, Rice GP, Kremenchutzky M, Ebers GC. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remittingmultiple sclerosis. Journal of neurology, neurosurgery, and psychiatry 2005;76(9):1294-6.
55. Yadav 2005 Yadav V, Marracci G, Lovera J, Woodward W, Bogardus K, Marquardt W, et al.Lipoic acid in multiple sclerosis: a pilot study. Multiple sclerosis 2005;11(2):159-65.
56. Zhang 2000 Zhang SM, Willett WC, Hernan MA, Olek MJ, Ascherio A. Dietary fat in relation to risk of multiple sclerosis among two large cohorts of women. American journal of epidemiology 2000;152(11):1056-64.
57. Zhang 2001 Zhang SM, Hernan MA, Olek MJ, Spiegelman D, Willett WC, Ascherio A. Intakes of carotenoids, vitamin C, and vitamin E and MS risk among two large cohorts of women. Neurology 2001;57(1):75-80.
58. Bourdette Bourdette D. Natural Antioxidants in the Treatment of Multiple Sclerosis. ClinicalTrials.gov.
59. Agranoff 1974 Agranoff BW, Goldberg D. Diet and the geographical distribution of multiple sclerosis. Lancet 1974;2:1061-6.
60. Alter 1974 Alter M, Yamoor M, Harshe M. Multiple sclerosis and nutrition. Archives of neurology 1974;31:267-72.
61. Auer 2000 Auer DP, Schumann EM, Kumpfel T, Gossl C, Trenkwalder C. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions inmultiple sclerosis. Annals of neurology 2000;47(2):276- 7.
62. Bates 1989 bis Bates D. Lipids andmultiple sclerosis. Biochemical Society transactions 1989;17:289-91.
63. Bowling 2003 Bowling AC, Stewart TM. Current Complementary and Alternative Therapies for Multiple Sclerosis. Current treatment options in neurology 2003;5:55-68.
64. Brown 2006 Brown SJ. The role of vitamin D in multiple sclerosis. The Annals of pharmacotherapy 2006;40(6):1158-61. Epub 2006 May 9.
65. Butcher 1976 Butcher J. The distribution of multiple sclerosis in relation to the dairy industry and milk consumption. The New Zealand medical journal 1976;83:427-30.
66. Cantorna 1996 Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America 1996;93(15): 7861-4.
67. Crellin 1990 Crellin RF, Bottiglieri T, Reynolds EH. Multiple sclerosis and macrocytosis. Acta neurologica Scandinavica 1990;81(5):388-91.
68. Das 2003 Das UN. Is there a role for saturated and long-chain fatty acids in multiple sclerosis?. Nutrition 2003;19:163-6.
69. Ebers 1998 Ebers P. Multiple sclerosis. in: DW Paty, GC Ebers (Eds.), Multiple sclerosis. Pennsylvania: FAQ Davis Company, 1998:404-420.
70. Esparza 1995 Esparza ML, Sasaki S, Kesteloot H. Nutrition, latitude, and multiple sclerosismortality: an ecologic study. American journal of epidemiology 1995;142:733-7.
71. Ferretti 2005 Ferretti G, Bacchetti T, Principi F, Di Ludovico F, Viti B, Angeleri VA, et al.Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Multiple sclerosis 2005;11(6):677-82.
72. Fischer 1999 Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Multiple Sclerosis 1999;5:251-259.
73. Ghadirian 1998 Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R. Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada. International journal of epidemiology 1998;27:845-52.
74. Ghezzi 2001 Ghezzi A, Zaffaroni M. Neurological manifestations of gastrointestinal disorders, with particular reference to the differential diagnosis of multiple sclerosis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2001;22 Suppl 2:S117-22.
75. Gilgun-Sherki 2004 Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. Journal of neurology 2004;251(3): 261-8.
76. Gupta 1977 Gupta JK, Ingegno AP, Cook AW, Pertschuk LP. Multiple sclerosis and malabsorption. The American journal of gastroenterology 1977;68(6):560-5.
77. Gusev 1996 Gusev E, Boiko A, Lauer K, Riise T, Deomina T. Environmental risk factors in MS: a case-control study in Moscow. Acta neurologica Scandinavica 1996;94:386-94.
78. Hayes 2000 Hayes CE. Vitamin D: a natural inhibitor of multiple sclerosis. The Proceedings of the Nutrition Society 2000;59(4): 531-5.
79. Kidd 2001 Kidd PM. Multiple sclerosis, an autoimmune inflammatory disease: prospects for its integrative management. Alternative medicine review : a journal of clinical therapeutic 2001;6(6):540-66.
80. Koch 2006 Koch MW, Ramsaransing GS, Arutjunyan AV, Stepanov M, Teelken A, Heersema DJ, et al. Oxidative stress in serumand peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. Journal of neurology 2006;253(4):483-7. Epub 2005 Nov 14.
81. Kurtzke 1983 Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33(11):1444-5.
82. Lange 1976 Lange LS, Shiner M. Small-bowel abnormalities in multiple sclerosis. Lancet 1976;2:1319-22.
83. Lauer 1991 Lauer K. The food pattern in geographical relation to the risk of multiple sclerosis in the Mediterranean and Near East region. Journal of epidemiology and community health 1991;45:251-2.
84. Lauer 1994 Lauer K. The risk of multiple sclerosis in the USA in relation to sociogeographic features: a factor-analytic study. Journal of clinical epidemiology 1994;47:43-8.
85. Lauer 1994 bis Lauer K, Finhaber W. Descriptive and analytical epidemiological data on multiple sclerosis from a long-term study in Southern Hesse, Germany. W. Firnhaber, K. Lauer (eds.). Multiple sclerosis in Europe: an epidemiological update. Germany: LTV Press, 1994:147-158.
86. Lauer 1995 Lauer K. Environmental associations with the risk of multiple sclerosis: the contribution of ecological studies. Acta neurologica Scandinavica. Supplementum 1995;161:77-88.
87. Lauer 1997 Lauer K. Diet and multiple sclerosis. Neurology 1997;49 (Suppl 2):S55-61.
88. Malosse 1992 Malosse D, Perron H, Sasco A, Seigneurin JM. Correlation between milk and dairy product consumption and multiple sclerosis prevalence: a worldwide study. Neuroepidemiology 1992;11:304-12.
89. McDonald 2001 McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al.Recommended diagnostic criteria for MS: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of neurology 2001;50:121-127.
90. Millar 1967 Millar JH, Vas CJ, Noronha MJ, Liversedge LA, Rawson MD. Long-term-treatment ofmultiple sclerosis with corticotrophin. Lancet 1967;2:429-31.
91. Miller 2005 Miller A, Korem M, Almog R, Galboiz Y. Vitamin B12, demyelination, remyelination and repair in multiple sclerosis. Journal of the neurological sciences 2005;233(1-2):93-7.
92. Murrell 1990 Murrell TG, Matthews BJ. Multiple sclerosis: one manifestation of neurobrucellosis?. Medical hypotheses 1990;33:43-8.
93. Nanji 1986 Nanji AA, Narod S. Multiple sclerosis, latitude and dietary fat: is pork the missing link?. Medical hypotheses 1986;20:279-82.
94. Poser 1983 Poser CM, Paty DW, Scheinberg L, McDonald WI, Devis FA, Ebers GC, et al.New diagnostic criteria for multiple sclerosis: guidelines for research protocol. Annals of Neurology 1983;13(3):227-31.
95. Rao 1991 Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991;41(5):685-91.
96. RevMan 4.2 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
97. Reynolds 1992 Reynolds EH, Bottiglieri T, Laundy M, Crellin RF, Kirker SG. Vitamin B12metabolism inmultiple sclerosis. Archives of neurology 1992;49(6):649-52.
98. Schumacher 1965 Schumacher GA, Beede GW, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, et al.Problems of experimental trials of therapy in multiple sclerosis: Report by the panel of evaluation of experimental trials in multiple sclerosis. Annals of the New York Academy of Sciences. 1965; Vol. 122:552-68.
99. Schwartz 1999 Schwartz CE, Laitin E, Brotman S, LaRocca N. Utilization of unconventional treatments by persons with MS: is it alternative or complementary?. Neurology 1999;52:626-9.
100. Schwarz 2005 Schwarz S, Leweling H. Multiple sclerosis and nutrition. Multiple sclerosis 2005;11:24-32.
101. Sepcic 1993 Sepcic J, Mesaros E, Materljan E, Sepic-Grahovac D. Nutritional factors and multiple sclerosis in Gorski Kotar, Croatia. Neuroepidemiology 1993;12:234-40.
102. Shatin 1964 Shatin R. Multiple Sclerosis and geography. New interpretation of epidemiological observations. Neurology 1964;14:338-44.
103. Shinto 2004 Shinto L, Calabrese C, Morris C, Sinsheimer S, Bourdette D. Complementary and alternative medicine in multiple sclerosis: survey of licensed naturopaths. Journal of alternative and complementary medicine 2004;10:891-7.
104. Siegfried 2003 N Siegfried, M Muller, J Volmink, J Deeks, M Egger, N Low, H Weiss, S Walker, P Williamson. Male circumcision for prevention of heterosexual acquisition of HIV in men. The Cochrane Database of Systematic Reviews 2003, Issue 3.Art. No.: CD003362. DOI:10.1002/14651858.CD003362.
105. Spach 2004 Spach KM, Pedersen LB, Nashold FE, Kayo T, Yandell BS, Prolla TA, et al.Gene expression analysis suggests that 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. Physiological genomics 2004;18(2):141-51.
106. Swank 1950 Swank RL. Multiple sclerosis; a correlation of its incidence with dietary fat. The American journal of the medical sciences 1950;220(4):421-30.
107. Swank 1952 Swank RL, Lerstad O, Strom A, Backer J. Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. The New England journal of medicine 1952;246:722-8.
108. Swank 2003 Swank RL, Goodwin JW. How saturated fats may be a causative factor in multiple sclerosis and other diseases. Nutrition 2003;19(5):478.
109. Tola 1994 Tola MR, Granieri E, Malagu S, Caniatti L, Casetta I, Govoni V, et al.Dietary habits and multiple sclerosis. A retrospective study in Ferrara, Italy. Acta neurologica 1994;16:189-97.
110. Vickrey 1995 Vickrey BG, Hays RD, Harooni R, Myers W, Ellison GW. A health-related quality of life measure for multiple sclerosis. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1995;4(3):187-206.
111. Vickrey 1997 Vickrey BG, Hays RD, Genovese BJ, Myers LW, Ellison GW. Comparison of a generic to disease-targeted health-related quality-of-life measures formultiple sclerosis. Journal of Clinical Epidemiology 1997;50(5):557-569.
112. Wender 1994 Wender M, Kazmierski R. The descriptive and analytical epidemiology of Multiple sclerosis in Western Poland. W. Firnhaber, K. Lauer (eds.). Multiple sclerosis in Europe: an epidemiological update. Germany: LTV Press, 1994:241-248.
113. www.MS-CAM.org www.ms-cam.org. Internet address.
114. www.WHO-UMC.org www.who-umc.org. Internet address.
115. Zorzon 2003 Zorzon M, Zivadinov R, Nasuelli D, Dolfini P, Bosco A, Bratina A, et al.Risk factors of multiple sclerosis: a case-control study. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2003;24:242-7.